Skip to content

13F-HR filed by NEA Management Company, LLC

NEA Management Company, LLC filed this 13F-HR for the quarter ended 2016-03-31, filed 2016-05-11, with 37 holding rows worth $1,505,839,000.

Accession
0001012975-16-001205
Filed
2016-05-11
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2016

A holdings report, 37 entries on the cover page, a total value of $1,505,839,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,505,839,000 with VALUE read as thousands by filing date, 13F file number 028-14302. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
TESARO INC881569107COM10,275,113$452,413,000thousands by filing date
GROUPON INC399473107COMMON STOCK44,172,953$176,250,000thousands by filing date
ARDELYX INC039697107COM11,792,631$91,629,000thousands by filing date
ADAPTIMMUNE THERAPEUTICS PLC00653A107SPONDS ADR9,880,999$80,333,000thousands by filing date
EPIZYME INC29428V104COM6,260,851$75,882,000thousands by filing date
SENSEONICS HLDGS INC81727U105COM26,303,189$75,227,000thousands by filing date
DERMIRA INC24983L104COM3,506,649$72,518,000thousands by filing date
OPOWER INC68375Y109COM8,997,290$61,272,000thousands by filing date
GLYCOMIMETICS INC38000Q102COM8,584,128$51,161,000thousands by filing date
LOXO ONCOLOGY INC548862101COM1,792,207$48,999,000thousands by filing date
NEVRO CORP64157F103COM660,428$37,156,000thousands by filing date
TREVENA INC89532E109COM3,811,691$31,523,000thousands by filing date
PROTEOSTASIS THERAPEUTICS IN74373B109COM3,095,240$29,838,000thousands by filing date
LEXICON PHARMACEUTICALS INC528872302COMMON STOCK2,382,286$28,468,000thousands by filing date
HIVE007786106Stock4,681,455$23,360,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM1,139,890$21,886,000thousands by filing date
ENDOLOGIX INC29266S106COM2,490,204$20,818,000thousands by filing date
CARE COM INC141633107COM3,260,989$20,055,000thousands by filing date
TRACON PHARMACEUTICALS INC89237H100COM1,889,652$13,209,000thousands by filing date
SYNLOGIC60470J103Stock2,974,811$13,000,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD2,141,308$9,764,000thousands by filing date
EXELIXIS INC COM30161Q104Stock2,207,000$8,828,000thousands by filing date
ZHONE TECHNOLOGIES INC NEW98950P884COM4,781,290$7,650,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock2,546,843$7,411,000thousands by filing date
RIGEL PHARMACEUTICALS INC766559603COMMON STOCK3,243,150$6,746,000thousands by filing date
AKARI THERAPEUTICS PLC009726108ADR438,780$6,143,000thousands by filing date
CHAMPIONS ONCOLOGY INC15870P307COM NEW1,562,500$5,688,000thousands by filing date
ARCA BIOPHARMA INC00211Y407COM PAR1,460,209$5,067,000thousands by filing date
Adobe Systems Inc98979H103COM2,158,543$4,965,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328601COM NEW7,789,644$4,206,000thousands by filing date
ARQULE INC04269E107COM2,520,316$4,033,000thousands by filing date
ROKA BIOSCIENCE INC775431109COM3,220,433$2,222,000thousands by filing date
CERECOR INC15671L109COM595,435$2,221,000thousands by filing date
OREXIGEN THERAPEUTICS INC686164104COMMON STOCK3,709,000$2,077,000thousands by filing date
PARATEK PHARMACEUTICALS INC699374302Equity125,004$1,896,000thousands by filing date
CATALYST14888D109COM652,380$1,096,000thousands by filing date
AGILE THERAPEUTICS INC00847L100COM133,488$829,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-16-001205this filing2016-05-11acceptance time not in the bulk data set